Anti-GD2 immunotherapy for neuroblastoma

Expert Review of Anticancer Therapy

Volumn 17, Issue 10, 2017, Pages 889-904

  Sait, Sameer ^a   Modak, Shakeel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

adoptive immunotherapy; anti cancer vaccines; GD2; immunotherapy; monoclonal antibodies; Neuroblastoma

Indexed keywords

ANTINEOPLASTIC AGENT; DINUTUXIMAB; GANGLIOSIDE GD2; IMMUNOCYTOKINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 14.G2A; MONOCLONAL ANTIBODY GD2; MONOCLONAL ANTIBODY HU14.18K322A; MONOCLONAL ANTIBODY HU3F8; MONOCLONAL ANTIBODY M3F8; UNCLASSIFIED DRUG; VACCINE; CANCER VACCINE; GANGLIOSIDE; GANGLIOSIDE, GD2;

ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CAPILLARY LEAK SYNDROME; CELL THERAPY; DRUG EFFECT; DRUG USE; FEVER; HUMAN; HYPERTENSION; NEUROBLASTOMA; NEUROTOXICITY; NONHUMAN; PAIN; RADIOIMMUNOTHERAPY; REVIEW; UNSPECIFIED SIDE EFFECT; URTICARIA; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; QUALITY OF LIFE; SURVIVAL RATE; TUMOR RECURRENCE;

ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; GANGLIOSIDES; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; QUALITY OF LIFE; SURVIVAL RATE;

EID: 85029419547     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1080/14737140.2017.1364995     Document Type: Review

References (121)

1. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet. 2007;369(9579):2106–2120.
2. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system:an INRG task force report. J Clin Oncol. 2009;27(2):289-297.
3. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–1334.•• This seminal randomized clinical trial conducted by the COG established anti-GD2 mAb therapy as the new standard of care for high-risk neuroblastoma.
4. Cheung NK, Cheung IY, Kushner BH, et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol. 2012;30(26):3264–3270.•• A summary of consecutive clinical trials of anti-GD2 mAb 3F8 conducted at MSKCC over 20 years and its curative potential.
5. Kreissman SG, Seeger RC, Matthay KK, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973):a randomised phase 3 trial. Lancet Oncol. 2013;14(10):999–1008.
6. Pearson AD, Pinkerton CR, Lewis IJ, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma:a randomised trial. Lancet Oncol. 2008;9(3):247–256.
7. Modak S, Cheung NK., Neuroblastoma:therapeutic strategies for a clinical enigma. Cancer Treat Rev. 2010;36(4):307–317.
8. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421.
9. Suzuki M, Cheung NK., Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin Ther Targets. 2015;19(3):349–362.
10. Yanagisawa M, Yoshimura S, Yu RK. Expression of GD2 and GD3 gangliosides in human embryonic neural stem cells. ASN Neuro. 2011;3(2).
11. Lammie GA, Cheung NKV, Gerald W, et al. Ganglioside GD2 expression in the human nervous system and in neuroblastomas–an immunohistochemical study. Int J Oncol. 1993;3:909–915.• This study demonstrated high GD2 expression on neuroblastoma tumors with restricted expression in the CNS and provided the basis for the investigation of anti-GD2 therapy using antibody 3F8.
12. Furukawa K, Soejima H, Niikawa N, et al. Genomic organization and chromosomal assignment of the human beta1, 4-N-acetylgalactosaminyltransferase gene. Identification of multiple transcription units. J Biol Chem. 1996;271(34):20836–20844.
13. Wu Z, Schwartz E, Seeger RC, et al. Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res. 1986;46:440–443.
14. Ohmi Y, Ohkawa Y, Yamauchi Y, et al. Essential roles of gangliosides in the formation and maintenance of membrane microdomains in brain tissues. Neurochem Res. 2012;37(6):1185–1191.
15. Kawakami K, Ahmed K, Utsunomiya Y, et al. Attachment of nontypable Haemophilus influenzae to human pharyngeal epithelial cells mediated by a ganglioside receptor. Microbiol Immunol. 1998;42(10):697–702.
16. Cheresh DA, Pierschbacher MD, Herzig MA, et al. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol. 1986;102:688.
17. Battula VL, Shi Y, Evans KW, et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest. 2012;122(6):2066–2078.
18. Julien S, Bobowski M, Steenackers A, et al. How do gangliosides regulate RTKs signaling? Cells. 2013;2(4):751–767.
19. Shibuya H, Hamamura K, Hotta H, et al. Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3. Cancer Sci. 2012;103(9):1656–1664.
20. Wondimu A, Liu Y, Su Y, et al. Gangliosides drive the tumor infiltration and function of myeloid-derived suppressor cells. Cancer Res. 2014;74(19):5449–5457.
21. Helling F, Livingston PO. Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origin. Mol Chem Neuropathol. 1994;21(2–3):299–309.
22. Dobrenkov K, Ostrovnaya I, Gu J, et al. Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. Pediatr Blood Cancer. 2016;63(10):1780–1785.
23. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens:a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323–5337.
24. Kramer K, Gerald WL, Kushner BH, et al. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Med Pediatr Oncol. 2001;36(1):194–196.
25. Schulz G, Cheresh DA, Varki NM, et al. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 1984;44:5914–5920.
26. Mora J. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma. Expert Rev Clin Pharmacol. 2016;9(5):647–653.
27. Cheung NK, Lazarus H, Miraldi FD, et al. Ganglioside GD2 specific monoclonal antibody 3F8:a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987;5(9):1430–1440.
28. Cheung NK, Kushner BH, Cheung IY, et al. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol. 1998;16(9):3053–3060.
29. Kushner BH, Kramer K, Cheung NKV. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol. 2001;19:4189–4194.
30. Cheung NK, Cheung IY, Kramer K, et al. Key role for myeloid cells:phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma. Int J Cancer Oncol. 2014;135(9):2199–2205.
31. Ahmed M, Hu J, Cheung NK. Structure based refinement of a humanized monoclonal antibody that targets tumor antigen disialoganglioside GD2. Front Immunol. 2014;5:372.
32. Cheung NK, Ostrovnaya I, Kuk D, et al. Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy. J Clin Oncol. 2015;33(7):755–763.
33. Kushner BH, Kramer K, Modak S, et al. Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma:a phase I study. J Clin Oncol. 2011;29(9):1168–1174.
34. Modak S, Kushner BH, Kramer K, et al. Anti-GD2 antibody 3F8 and barley-derived (1 –> 3),(1 –> 4)-beta-D-glucan:a phase I study in patients with chemoresistant neuroblastoma. Oncoimmunology. 2013;2(3):e23402.
35. Modak S, Kushner B, Kramer K, et al. Phase I study of combination of anti-GD2 antibody 3F8 and soluble yeast-derived beta glucan for resistant neuroblastoma. Proc ANR Meeting (Abs). 2008;169.
36. Murray JL, Cunningham JE, Brewer HM, et al. Phase I trial of murine anti-ganglioside (GD2) monoclonal antibody (Mab) 14G2A in cancer patients. J Biol Resp Modif. Abs.1991;135.
37. Murray JL, Cunningham JE, Brewer H, et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol. 1994;12(1):184–193.
38. Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch 14.18 in patients with neuroblastoma. Eur J Cancer. 1995;31:261–267.
39. Yu A, Uttenreuther-Fischer M, Huang C-S, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol. 1998;16:2169–2180.
40. Gilman AL, Ozkaynak MF, Matthay KK, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue:a report from the Children’s Oncology Group. J Clin Oncol. 2009;27(1):85–91.
41. Simon T, Hero B, Faldum A, et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer. 2011;11:21.
42. Mody R, Naranjo A, van Ryn C, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221):an open-label, randomised, phase 2 trial. Lancet Oncol. 2017;18(7):946–957.
43. Ladenstein R, Weixler S, Baykan B, et al. Ch14.18 antibody produced in CHO cells in relapsed or refractory stage 4 neuroblastoma patients:a SIOPEN phase 1 study. MAbs. 2013;5(5):801–809.
44. Siebert N, Eger C, Seidel D, et al. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. MAbs. 2016;8(3):604–616.
45. Ladenstein R, Poetschger U, Gray JA, et al. Toxicity and outcome of anti-GD2 antibody ch14.18/CHO in front-line, high-risk patients with neuroblastoma:final results of the phase III immunotherapy randomisation (HR-NBL1/SIOPEN trial). J Clin Oncol (Suppl) 2016;34. Abstr 10500.
46. Osenga KL, Hank JA, Albertini MR, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma:a study of the Children’s Oncology Group. Clin Cancer Res. 2006;12(6):1750–1759.
47. Kushner B, Cheung IY, Basu E, et al. Phase I study of anti-GD2 humanized 3F8 plus GM-CSF:high dosing and major responses in patients with resistant high-risk neuroblastoma. Adv Neuroblastoma Res 2016;2016. Abs 57.
48. Shusterman S, London WB, Gillies SD, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma:a Children’s Oncology Group (COG) phase II study. J Clin Oncol. 2010;28(33):4969–4975.
49. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med. 1999;341(16):1165–1173.
50. Cheung NK, Kushner BH, LaQuaglia M, et al. N7:a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol. 2001;36(1):227–230.
51. Modak S, Kushner B, Kramer K, et al. Combined radioimmunotherapy and anti-angiogenic therapy for resistant neuroblastoma. Proc ANR Meeting (Abs). 2010;137.
52. Modak S, Cheung NK, Kushner B, et al. Phase I study of haploidentical NK cells plus monoclonal antibody 3F8 for resistant high-risk neuroblastoma. Proc ANR Meeting (Abs). 2014.
53. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors:persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264–1270.
54. Foon KA, Lutzky J, Baral RN, et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol. 2000;18:376–384.
55. Ragupathi G, Livingston PO, Hood C, et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res. 2003;9(14):5214–5220.
56. Cheung NK, Dyer MA. Neuroblastoma:developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013;13(6):397–411.
57. Liu Y, Xiao L, Joo KI, et al. In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice. Biomacromolecules. 2014;15(10):3836–3845.
58. Imai M, Landen C, Ohta R, et al. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res. 2005;65(22):10562–10568.
59. Baxevanis CN, Tsavaris NB, Papadhimitriou SI, et al. Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy:correlation with clinical responses. Eur J Cancer. 1997;33(8):1202–1208.
60. Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5(6):e1163462.
61. Kushner BH, Cheung NKV. Nonoxidative lysis of human solid tumor cells by neutrophils armed with GD2 specific monoclonal antibody 3F8. Blood. 1991;51(18):4865-4870.
62. Kowalczyk A, Gil M, Horwacik I, et al. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells. Cancer Lett. 2009;281(2):171–182.
63. Kushner BH, Cheung NK. Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes. Cancer Res. 1991;51(18):4865–4870.
64. Saarinen UM, Coccia PF, Gerson SL, et al. Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement:method for purging autologous bone marrow. Cancer Res. 1985;45:5969–5975.
65. Cheung NK, Modak S. Oral (1–>3),(1–>4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res. 2002;8(5):1217–1223.
66. Modak S, Cheung NK. Antibody-based targeted radiation to pediatric tumors. J Nucl Med. 2005;46(Suppl 1):157S–163S.
67. Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood. 1989;73(7):1936–1941.
68. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid:a Children’s Oncology Group study. J Clin Oncol. 2009;27(7):1007–1013.
69. Kushner BH, Ostrovnaya I, Cheung IY, et al. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget. 2016;7(4):4155–4166.
70. Kushner BH, Ostrovnaya I, Cheung IY, et al. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin:a prospective phase II study. Oncoimmunology. 2015;4(7):e1016704.
71. Cheung NK, Cheung IY, Canete A, et al. Antibody response to murine anti-GD2 monoclonal antibodies:correlation with patient survival. Cancer Res. 1994;54(8):2228–2233.
72. Modak S, Kushner B, Kramer K, et al. Suppression of human anti-mouse antibody response by rituximab plus cyclophosphamide permits continuation of anti-GD2 immunotherapy. Proc ANR Meeting (Abs). 2010;104.
73. Cheung NK, Guo HF, Heller G, et al. Induction of Ab3 and Ab3ʹ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin Cancer Res. 2000;6(7):2653–2660.
74. Mujoo K, Kipps TJ, Yang HM, et al. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res. 1989;49:2857–2861.
75. Uttenreuther-Fischer MM, Huang CS, Reisfeld RA, et al. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients. Cancer Immunol Immunother. 1995;41(1):29–36.
76. Gillies SD, Lo K-M, Wesolowski J. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods. 1989;125:191–202.
77. Mueller BM, Romerdahl CA, Gillies SD, et al. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol. 1990;144(4):1382–1386.
78. Ozkaynak MF, Sondel PM, Krailo MD, et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation:a Children’s Cancer Group study. J Clin Oncol. 2000;18(24):4077–4085.
79. Yu A, Gilman A, Ozkaynak MF, et al. Update of outcome for high-risk neuroblastoma treated on a randomized trial of chimeric anti-GD2 antibody (ch14.18)+GMCSF-IL2 immunotherapy in 1st response:a Children’s Oncology Group study. Proc ANR Meeting (Abs). 2014;108.
80. Xu Y, Sun J, Sheard MA, et al. Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFbeta1. Cancer Immunol Immunother. 2013;62(10):1637–1648.
81. Zeng Y, Fest S, Kunert R, et al. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol. 2005;42(11):1311–1319.
82. Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol. 1998;16(6):2169–2180.
83. Kashmiri SV, De Pascalis R, Gonzales NR, et al. SDR grafting–a new approach to antibody humanization. Methods. 2005;36(1):25–34.
84. Cheung NK, Guo H, Hu J, et al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology. 2012;1(4):477–486.
85. Basu EM, Kushner BH, Modak S, et al. Phase I study of humanized 3F8 monoclonal antibody in patients with relapsed or refractory neuroblastoma. Proc ANR Meeting (Abs). 2012;115.
86. Cheung I, Basu E, Modak S, et al. Pharmacokinetics of humanized anti-GD2 monoclonal antibody hu3F8 in patients with metastatic GD2-positive tumors. Proc ANR Meeting (Abs). 2014;243.
87. Navid F, Sondel PM, Barfield R, et al. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol. 2014;32(14):1445–1452.
88. Anghelescu DL, Goldberg JL, Faughnan LG, et al. Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma. Pediatr Blood Cancer. 2015;62(2):224–228.
89. Pancook JD, Becker JC, Gillies SD, et al. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunol Immunother. 1996;42(2):88–92.
90. Hank JA, Surfus JE, Gan J, et al. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch 14.18-IL2). Clin Cancer Res. 1996;2:1951–1959.
91. Yu AL, Batova A, Alvarado C, et al. Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma:a POG phase II study. Proc ASCO. 1997;16:1846.
92. Kramer K, Humm JL, Souweidane MM, et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol. 2007;25(34):5465–5470.
93. Kramer K, Kushner BH, Modak S, et al. Compartmental intrathecal radioimmunotherapy:results for treatment for metastatic CNS neuroblastoma. J Neurooncol. 2010;97(3):409–418.• Intrathecal administration of anti-GD2 antibodies could improve the cure rate after CNS neuroblastoma metastases.
94. Tarek N, Le Luduec JB, Gallagher MM, et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest. 2012;122(9):3260–3270.
95. Delgado DC, Hank JA, Kolesar J, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010;70(23):9554–9561.
96. Forlenza CJ, Boudreau JE, Zheng J, et al. KIR3DL1 allelic polymorphism and HLA-B epitopes modulate response to anti-GD2 monoclonal antibody in patients with neuroblastoma. J Clin Oncol. 2016;34(21):2443–2451.
97. Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118(23):6050–6056.
98. Bhutani D, Lum LG. Activated T cells armed with bispecific antibodies kill tumor targets. Curr Opin Hematol. 2015;22(6):476–483.
99. Cheung NK, Canete A, Cheung IY, et al. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. Int J Cancer Oncol. 1993;54(3):499–505.
100. Kushner BH, Cheung IY, Modak S, et al. Phase I trial of a bivalent gangliosides vaccine in combination with beta-glucan for high-risk neuroblastoma in second or later remission. Clin Cancer Res. 2014;20(5):1375–1382.• Active immunity elicited by anti-GD2 (and anti-GD3) vaccine when combined with the immune adjuvant QS21 and oral glucan appears to improve survival rates for NB patients in second CR.
101. Ahmed M, Goldgur Y, Hu J, et al. In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors. PloS One. 2013;8(5):e63359.
102. Xu H, Guo H, Cheung IY, et al. Antitumor efficacy of anti-GD2 IgG1 is enhanced by Fc glyco-engineering. Cancer Immunol Res. 2016;4(7):631–638.
103. Cheung NK, Modak S, Lin Y, et al. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. J Nucl Med. 2004;45(5):867–877.
104. Cheal SM, Xu H, Guo HF, et al. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol Cancer Ther. 2014;13(7):1803–1812.• A pretargeting strategy using an anti-GD2 bispecific antibody substantially improves therapeutic index.
105. Raffaghello L, Pagnan G, Pastorino F, et al. In vitro and in vivo antitumor activity of liposomal fenretinide targeted to human neuroblastoma. Int J Cancer Oncol. 2003;104(5):559–567.
106. Brignole C, Pastorino F, Marimpietri D, et al. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J Natl Cancer Inst. 2004;96(15):1171–1180.
107. Tivnan A, Orr WS, Gubala V, et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PloS One. 2012;7(5):e38129.
108. Di Paolo D, Pastorino F, Zuccari G, et al. Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma. J Control Release. 2013;170(3):445–451.
109. Wang CH, Huang YJ, Chang CW, et al. In vitro photothermal destruction of neuroblastoma cells using carbon nanotubes conjugated with GD2 monoclonal antibody. Nanotechnology. 2009;20(31):315101.
110. Thomas PB, Delatte SJ, Sutphin A, et al. Effective targeted cytotoxicity of neuroblastoma cells. J Pediatr Surg. 2002;37(3):539–544.
111. Vincent M, Bessard A, Cochonneau D, et al. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency. Int J Cancer Oncol. 2013;133(3):757–765.
112. Yong CSM, Dardalhon V, Devaud C, et al. CAR T-cell therapy of solid tumors. Immunol Cell Biol. 2017;95(4):356–363.
113. Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581–590.
114. Gargett T, Yu W, Dotti G, et al. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol Ther. 2016;24(6):1135–1149.
115. Heczey A, Louis CU. Advances in chimeric antigen receptor immunotherapy for neuroblastoma. Discov Med. 2013;16(90):287–294.
116. Zhao XJ. GD2 oligosaacharide:target for cytotoxic T-lymphocyte (CTL). Cancer Res. 1995;182(1);67-74.
117. Cheng M, Santich BH, Xu H, et al. Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors. Oncoimmunology. 2016;5(6):e1168557.
118. Terme M, Dorvillius M, Cochonneau D, et al. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. PloS One. 2014;9(2):e87210.
119. Lammerts van Bueren JJ, Rispens T, Verploegen S, et al. Anti-galactose-alpha-1,3-galactose IgE from allergic patients does not bind alpha-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol. 2011;29(7):574–576.
120. Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 2014;588(2):288-297.
121. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–195.